<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03153150</url>
  </required_header>
  <id_info>
    <org_study_id>SoSTART2016</org_study_id>
    <secondary_id>2016-004121-16</secondary_id>
    <nct_id>NCT03153150</nct_id>
  </id_info>
  <brief_title>Start or STop Anticoagulants Randomised Trial (SoSTART)</brief_title>
  <acronym>SoSTART</acronym>
  <official_title>Start or STop Anticoagulants Randomised Trial (SoSTART) After Spontaneous Intracranial Haemorrhage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Edinburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NHS Lothian</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Edinburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary research question: For adults surviving spontaneous (non-traumatic) symptomatic
      intracranial haemorrhage with persistent/paroxysmal atrial fibrillation/flutter (AF), does
      starting full treatment dose oral anticoagulation (OAC) result in a beneficial net reduction
      of all serious vascular events compared with not starting OAC?

      Trial design: Investigator-led, multicentre, randomised, open, assessor-masked, parallel
      group, clinical trial of investigational medicinal product (CTIMP) prescribing strategies.
      Investigators plan for a pilot phase, followed by a main phase.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bleeding within the skull, also known as brain haemorrhage, affects 3 million people in the
      world each year.

      One in five people who survive brain haemorrhage have an irregular heart rhythm called
      'atrial fibrillation', which puts them at risk of stroke and other blood clots.

      Blood-thinning medicines, known as 'anticoagulant' drugs, are used in everyday clinical
      practice to protect people with atrial fibrillation from developing blood clots. However,
      these drugs also increase the risk of bleeding and are usually stopped when the brain
      haemorrhage occurs.

      But when patients recover from brain haemorrhage, they and their doctors are often uncertain
      about whether to start or stop these drugs to prevent further clots occurring, or whether to
      avoid them in case they increase the risk of brain haemorrhage happening again.

      Investigators want to find out whether starting or not starting an anticoagulant drugs is
      better for those patients.

      A network of hospital doctors, nurses, and other staff will identify people who survive brain
      haemorrhage and have atrial fibrillation. If a patient and their doctor are uncertain about
      whether to start an anticoagulant drug, they may invite the patient to participate.

      In the pilot phase, investigators aim to recruit at least 60 participants to determine the
      feasibility of recruiting the target sample size of at least 800 participants in the main
      phase of the trial.

      Investigators will follow-up all participants for at least one year to determine whether
      prescribing an anticoagulant drug reduces the occurrence of all serious vascular events like
      heart attack, stroke compared with a policy of avoiding oral anticoagulant.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 28, 2018</start_date>
  <completion_date type="Anticipated">July 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>1:1 allocation of intervention: comparator, using a minimisation algorithm</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>PROBE design</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>The number of participants recruited per site per month (in the pilot phase of the trial)</measure>
    <time_frame>1 year after trial initiation</time_frame>
    <description>The rate of recruiting up to 60 participants to determine the feasibility of recruiting the target sample size in the main phase of the trial in an acceptable timescale.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The incidence rate of the first occurrence of the composite outcome of all symptomatic serious vascular events (in the main phase of the trial)</measure>
    <time_frame>1 year after randomisation</time_frame>
    <description>The composite outcome will comprise:
Non-fatal acute coronary syndrome (i.e. not followed by death within 30 days of onset)
Non-fatal stroke (i.e. ischaemic, haemorrhagic or unknown sub-type, not followed by death within 30 days of onset)
Death from a vascular cause (i.e. haemorrhagic or ischaemic events followed by death within 30 days), sudden death, or death of an unknown cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportions of all eligible patients recorded on screening logs who are recruited, unsuitable, or decline to participate (in the pilot phase of the trial)</measure>
    <time_frame>1 year after randomisation</time_frame>
    <description>The acceptability of the trial protocol to investigators and patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence rate of the first occurrence of each individual symptomatic serious vascular event type (in the main phase of the trial)</measure>
    <time_frame>1 year after randomisation</time_frame>
    <description>Major haemorrhagic events:
Fatal bleeding, and/or
Symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intra-articular or pericardial, or intramuscular with compartment syndrome, and/or
Bleeding causing a fall in haemoglobin level of 20 g/l (1.24 mmol/l) or more, or leading to transfusion of two or more units of whole blood or red cells
Symptomatic ischaemic events:
transient ischaemic attack
ischaemic stroke
acute coronary syndrome
peripheral arterial occlusion/insufficiency
mesenteric ischaemia
retinal arterial occlusion
deep vein thrombosis
pulmonary embolism
cardiac death with symptoms suggestive of myocardial ischaemia (type 3), or evidence of arrhythmia
Revascularisation procedures (carotid, coronary, or peripheral arterial)
Symptomatic stroke of uncertain sub-type
Individual types of fatal events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of participants in each category of death or dependence on the modified Rankin Scale (in the main phase of the trial)</measure>
    <time_frame>1 year after randomisation</time_frame>
    <description>modified Rankin Scale score, collected using structured questions, completed by the participant, their carer or a nominated contact</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Intracranial Hemorrhages</condition>
  <condition>Intracranial Hemorrhage, Hypertensive</condition>
  <condition>Subarachnoid Hemorrhage</condition>
  <condition>Subdural Hematoma</condition>
  <condition>Intraventricular Hemorrhage</condition>
  <condition>Atrial Fibrillation</condition>
  <condition>Atrial Flutter</condition>
  <condition>Small Vessel Cerebrovascular Disease</condition>
  <condition>Microhaemorrhage</condition>
  <arm_group>
    <arm_group_label>Start oral anticoagulant (OAC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>If the patient is randomized in this arm, an oral anticoagulant:
Factor Xa inhibitors: Apixaban or Rivaroxaban or Edoxaban or
Direct thrombin inhibitor: Dabigatran or
Vitamin K antagonists: Acenocoumarol or Phenindione or Warfarin chosen by the patient's physician before the randomisation, will be prescribed long-term (â‰¥1 year) to the patient.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Do not start oral anticoagulant (OAC)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>If the patient is randomized in this arm, anticoagulant drugs will not be prescribed to the patient during the entire study period. The standard clinical practice without OAC may include:
antiplatelet drug(s) or
no antithrombotic drugs.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apixaban</intervention_name>
    <description>The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.</description>
    <arm_group_label>Start oral anticoagulant (OAC)</arm_group_label>
    <other_name>Eliquis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rivaroxaban</intervention_name>
    <description>The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.</description>
    <arm_group_label>Start oral anticoagulant (OAC)</arm_group_label>
    <other_name>Xarelto</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Edoxaban</intervention_name>
    <description>The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.</description>
    <arm_group_label>Start oral anticoagulant (OAC)</arm_group_label>
    <other_name>Lixiana</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran</intervention_name>
    <description>The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.</description>
    <arm_group_label>Start oral anticoagulant (OAC)</arm_group_label>
    <other_name>Pradaxa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acenocoumarol</intervention_name>
    <description>The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.</description>
    <arm_group_label>Start oral anticoagulant (OAC)</arm_group_label>
    <other_name>Sinthrome</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phenindione</intervention_name>
    <description>The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.</description>
    <arm_group_label>Start oral anticoagulant (OAC)</arm_group_label>
    <other_name>Dindevan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin</intervention_name>
    <description>The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.</description>
    <arm_group_label>Start oral anticoagulant (OAC)</arm_group_label>
    <other_name>Marevan</other_name>
    <other_name>Coumadin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient age â‰¥18 years

          2. Intracranial haemorrhage (i.e. intracerebral haemorrhage, non-aneurysmal subarachnoid
             haemorrhage,intraventricular haemorrhage, or subduralhaemorrhage)

               -  Not attributable to a known underlying intracranial aneurysm, arteriovenous
                  malformation, cerebral cavernous malformation, dural arteriovenous fistula,
                  intracranial venous thrombosis

               -  Not attributable to known head injury, based on:

               -  a history from the patient/witness of spontaneous symptom onset without preceding
                  head trauma (head trauma occurring after symptom onset is permissible)

               -  brain imaging appearances consistent with spontaneous intracranial haemorrhage
                  (which may be accompanied by the brain/bone/soft tissue appearances of trauma
                  occurring subsequently)

          3. Atrial fibrillation/flutter (persistent or paroxysmal) with a CHA2DS2-VASc score â‰¥2

          4. If included in the brain magnetic resonance imaging (MRI) sub-study, the scan must be
             done after intracranial haemorrhage and before randomisation

        Exclusion Criteria:

          1. Intracranial haemorrhage within the last 24 hours (when the risk of haemorrhage
             expansion/growth is greatest)

          2. Intracranial haemorrhage is exclusively due to trauma or haemorrhagic transformation
             of ischaemic stroke

          3. Prosthetic mechanical heart valve or severe (haemodynamically significant) native
             valve disease

          4. Intention to perform left atrial appendage occlusion for prevention of systemic
             embolism in AF

          5. Intention to start antiplatelet drug(s) if randomised to start full dose OAC

          6. Intention to start OAC if randomised to either start antiplatelet drugs or avoid all
             antithrombotic drugs

          7. Intention to implement the allocated treatment strategy for &lt;1 year

          8. Patient or their doctor is certain about whether to start or avoid full dose OAC

          9. Brain imaging that first diagnosed the intracranial haemorrhage is not available

         10. Patient is not registered with a general practitioner

         11. Patient is pregnant, breastfeeding, or of childbearing age and not taking
             contraception

         12. Patient and carer unable to understand spoken or written English

         13. Contraindications to any of the IMPs, other than recent intracranial haemorrhage

         14. Contraindication to MRI (brain MRI sub-study)

         15. Life expectancy less than one year

         16. Previously randomised in SoSTART
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rustam Al-Shahi Salman, MA PhD FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Edinburgh</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rustam Al-Shahi Salman, MA PhD FRCP</last_name>
    <phone>(0044) 0131 465 9602</phone>
    <email>rustam.al-shahi@ed.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kasia Adamczuk, MSc</last_name>
    <phone>(0044) 0131 465 9592</phone>
    <email>Kasia.Adamczuk@ed.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Edinburgh Royal Infirmary</name>
      <address>
        <city>Edinburgh</city>
        <state>Midlothian</state>
        <zip>EH16 4SB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rustam Al-Shahi Salman, MA PhD FRCP</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aberdeen Royal Infirmary</name>
      <address>
        <city>Aberdeen</city>
        <zip>AB25 2ZN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mary Joan MacLeod</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nevill Hall Hospital</name>
      <address>
        <city>Abergavenny</city>
        <zip>NP7 7EG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bella Richard</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Monklands Hospital</name>
      <address>
        <city>Airdrie</city>
        <zip>ML6 0JS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Baber</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Barnet Hospital</name>
      <address>
        <city>Barnet</city>
        <zip>EN5 3DJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sam Qureshi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal United Hospital</name>
      <address>
        <city>Bath</city>
        <zip>BA1 3NG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Choulerton</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bradford Royal Infirmary</name>
      <address>
        <city>Bradford</city>
        <zip>BD9 6RJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hawraman Ramadan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Bristol</name>
      <address>
        <city>Bristol</city>
        <zip>BS2 8HW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clare Holmes</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Altnagelvin Hospital</name>
      <address>
        <city>Derry</city>
        <zip>BT47 6SB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mark McCarron</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Doncaster Royal Infirmary</name>
      <address>
        <city>Doncaster</city>
        <zip>DN2 5LT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Manohar Kini</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Devon &amp; Exeter Hospital</name>
      <address>
        <city>Exeter</city>
        <zip>EX2 5DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Mudd</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth University Hospital</name>
      <address>
        <city>Glasgow</city>
        <zip>G51 4TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Keith Muir</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Calderdale Royal Hospital</name>
      <address>
        <city>Halifax</city>
        <zip>HX3 0PW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anand Nair</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwick Park</name>
      <address>
        <city>Harrow</city>
        <zip>HA1 3UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Cohen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Victoria Hospital Kirkcaldy</name>
      <address>
        <city>Kirkcaldy</city>
        <zip>KY2 5AH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vera Cvoro</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leeds General Infirmary</name>
      <address>
        <city>Leeds</city>
        <zip>LS13EX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Vasileios Papavasileiou</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>North Middlesex University Hospital</name>
      <address>
        <city>London</city>
        <zip>N18 1QX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Robert Luder</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University College London Hospital</name>
      <address>
        <city>London</city>
        <zip>NW1 2BU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David Werring</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St Thomas Hospital</name>
      <address>
        <city>London</city>
        <zip>SE1 7EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anthony Rudd</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>St.George's Hospital</name>
      <address>
        <city>London</city>
        <zip>SW17 OQT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gilian Cluckie</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>James Cook University Hospital</name>
      <address>
        <city>Middlesbrough</city>
        <zip>TS4 3BW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Samer Al-Hussayni</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nottingham City Hospital</name>
      <address>
        <city>Nottingham</city>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Senthil Raghunathan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Queen Alexandra Hospital</name>
      <address>
        <city>Portsmouth</city>
        <zip>PO6 3LY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shivaprasad Siddegowda</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Preston Hospital</name>
      <address>
        <city>Preston</city>
        <zip>PR2 9HT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hedley Emsley</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Salford Royal NHS Foundation Trust</name>
      <address>
        <city>Salford</city>
        <zip>M6 8HD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adrian Parry-Jones</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Hallamshire Hospital</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2JF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kirsty Harkness</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nic Weir</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Stoke University Hospital</name>
      <address>
        <city>Stoke-on-Trent</city>
        <zip>ST4 6QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Girish Muddegowda</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Morriston Hospital</name>
      <address>
        <city>Swansea</city>
        <zip>SA6 6NL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tal Anjum</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Torbay District General Hospital</name>
      <address>
        <city>Torquay</city>
        <zip>TQ2 7AA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Biju Bhaskaran</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>New Cross Hospital</name>
      <address>
        <city>Wolverhampton</city>
        <zip>WV10 0QP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ken Fotherby</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yeovil District Hospital</name>
      <address>
        <city>Yeovil</city>
        <zip>BA21 4AT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Khalid Rashed</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.sostart.ed.ac.uk</url>
    <description>Trial website</description>
  </link>
  <link>
    <url>http://www.ed.ac.uk/clinical-brain-sciences/people/principal-investigators/professor-rustam-al-shahi-salman</url>
    <description>Chief investigator details</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 10, 2017</study_first_submitted>
  <study_first_submitted_qc>May 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2017</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Oral anticoagulant</keyword>
  <keyword>Factor Xa inhibitors</keyword>
  <keyword>Direct thrombin inhibitor</keyword>
  <keyword>Vitamin K antagonist</keyword>
  <keyword>Antiplatelet drug</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Subarachnoid Hemorrhage</mesh_term>
    <mesh_term>Hematoma</mesh_term>
    <mesh_term>Atrial Flutter</mesh_term>
    <mesh_term>Intracranial Hemorrhages</mesh_term>
    <mesh_term>Cerebrovascular Disorders</mesh_term>
    <mesh_term>Cerebral Hemorrhage</mesh_term>
    <mesh_term>Hematoma, Subdural</mesh_term>
    <mesh_term>Intracranial Hemorrhage, Hypertensive</mesh_term>
    <mesh_term>Cerebral Small Vessel Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apixaban</mesh_term>
    <mesh_term>Edoxaban</mesh_term>
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Rivaroxaban</mesh_term>
    <mesh_term>Dabigatran</mesh_term>
    <mesh_term>Anticoagulants</mesh_term>
    <mesh_term>Acenocoumarol</mesh_term>
    <mesh_term>Phenindione</mesh_term>
    <mesh_term>Factor Xa Inhibitors</mesh_term>
    <mesh_term>Antithrombins</mesh_term>
    <mesh_term>Platelet Aggregation Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The Chief Investigator (Prof. Rustam Al-Shahi Salman) has established the Collaboration Of Controlled Randomised trials of Oral Antithrombotic drugs after intraCranial Haemorrhage (COCROACH) working towards a pre-planned individual patient data meta-analysis</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

